araag2/HINT huggingface dataset:
Clinical trial NCT00003625 (phase 1, status: completed)
Conditions: brain tumors, central nervous system tumors
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6, C72.9, D33.9, D43.9, D33.7, D43.8
Drugs: cyclosporine, etoposide, vincristine sulfate
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS: Newly diagnosed diffuse intrinsic brain stem glioma by MRI Biopsy
        is neither necessary nor encouraged A least two-thirds of the tumor is in the pons Origin
        of the tumor is clearly in the pons Must be registered within 28 days of diagnosis Clinical
        history less than 6 months duration (cranial nerve deficit, long tract signs, or ataxia) No
        diffuse leptomeningeal disease

        PATIENT CHARACTERISTICS: Age: 3 to 21 Performance status: Karnofsky or Lansky 50-100% Life
        expectancy: At least 6 weeks Hematopoietic: Absolute neutrophil count at least 1,000/mm3
        Platelet count at least 75,000/mm3 Hepatic: SGPT less than 2 times normal Renal: Creatinine
        normal for age OR Creatinine clearance greater than 70 mL/min

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
        prior chemotherapy No other concurrent chemotherapy Endocrine therapy: Prior steroids at
        stable or decreasing doses allowed Radiotherapy: No prior radiotherapy Surgery: Not
        specified Other: No other concurrent investigational agents
Clinical trial NCT01088191 (phase 1/phase 2, status: completed)
Conditions: anterior cruciate ligament injury, osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: hyaluronan
SMILES: CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males or females at least 18 years of age, but not older than 40

          2. ACL injury requiring reconstruction

          3. Have undergone unilateral ACL reconstruction surgery within six months of injury;

          4. Willing and able to undertake a standardized rehabilitation protocol

          5. ACL graft used is autograft

          6. Willingness to participate in follow-up for 24 months from the time of initial
             treatment

          7. Ability to understand and willingness to sign consent form

        Exclusion Criteria:

          1. Women who are pregnant or breast feeding or planning to become pregnant during the
             study

          2. Previous allergic reaction to Hyaluronan

          3. Systemic or local infection at the screen visit or at the time of the study injection

          4. History of any autoimmune disease, such as, systemic lupus erythematosus, Addison's
             disease, Crohn's disease, or rheumatoid arthritis

          5. Treatment with immunosuppression therapy within 6 months prior to screen (visit 1)

          6. Acute or chronic infectious disease, including but not limited to human
             immunodeficiency virus (HIV);

          7. Treatment and /or uncompleted follow-up treatment of any investigational therapy
             within 6 months before the procedure and /or intent to participate in any other
             investigational drug or cell therapy study during the 24 month follow-up period of
             this study;

          8. Recipient of prior allogeneic stem cell/progenitor cell therapy

          9. Undergoing a simultaneous procedure to the opposite knee

         10. 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody
             specificities to donor HLA antigens;

         11. Known sensitivities to bovine (cow), murine (mouse), chicken products and/or
             dimethylsulfoxide (DMSO). Previous allergic reaction to Hyaluronan;

         12. History or current evidence of alcohol or drug abuse or is a recreational user of
             illicit drugs or prescription medications

         13. History of prior surgery to the study knee joint

         14. History of malignancy (excluding basal cell carcinoma that has been successfully
             excised)

         15. Chondral lesions noted at time of surgical reconstruction greater than Grade 1a on any
             surfaces
Clinical trial NCT00679055 (phase 1, status: terminated)
Conditions: peripheral vascular diseases
ICD codes: I73.9, I73.89
Drugs: mk-0736, comparator: placebo (unspecified)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with peripheral arterial disease

          -  Participants must be 18 to 85 years of age

          -  Females must be postmenopausal or sterile

        Exclusion Criteria:

          -  Participans with hepatic, HIV, endocrine, connective tissue, psychiatric disorders or
             uncontrolled hypertension
Clinical trial NCT01026233 (phase 1, status: completed)
Conditions: disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin
ICD codes: C81.77, C81.97, C81.17, C81.27, C81.37, C81.47, C81.70, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: brentuximab vedotin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory CD30-positive malignancy

          -  Adequate organ function

          -  ECOG performance status <2

        Exclusion Criteria:

          -  Cardiac abnormalities (abnormal rhythm, history of significant cardiac event)

          -  Current diagnosis of primary cutaneous ALCL

          -  Acute or chronic graft-versus-host disease

          -  Prior hematopoietic stem cell transplant within specified timeframe
Clinical trial NCT01175395 (phase 1/phase 2, status: completed)
Conditions: age-related macular degeneration, choroidal neovascularization
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190, H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: ibi-20089/lucentis
SMILES: [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Male or Female subjects, 55 years of age and older.

          2. Diagnosis of active, subfoveal choroidal neovascular membranes (CNVM) due to age
             related macular degeneration (AMD)

          3. Visual acuity from 20/25 to 20/400 in the study eye.

        Exclusion Criteria:

          1. Subjects who have received corticosteroids via any route in the past 30 days.

          2. In the opinion of the investigator, patient is known to be a steroid-responder.

          3. Subjects with a history of uncontrolled glaucoma (Primary or Secondary)

          4. History of ocular surgery (invasive or non-invasive) in the past 90 days

          5. Intravitreal treatment with an anti-VEGF agent e.g. bevacizumab, ranibizumab, or
             pegaptanib within 30 days of the enrollment (Day 0) examination.

          6. Patients requiring systemic steroids (greater than 15 mg daily by mouth) or systemic
             immunomodulatory agents.

          7. Active ocular or periocular infection (i.e., bacterial, viral, parasitic or fungal) in
             either eye or a history of herpetic ocular infection in either eye.

          8. Media opacity in the study eye precluding observation or photography of the fundus.

          9. Any other clinically significant medical or psychological condition that, in the
             opinion of the Investigator, would jeopardize the safety of the patient or affect the
             validity of the study results.

         10. Participation in a clinical trial of an investigational drug or device within 30 days
             of the screening visit.

         11. Known history of allergy to corticosteroids.

         12. Pregnant or lactating women
Clinical trial NCT00415636 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ic83/ly2603618, ic83/ly2603618, ic83/ly2603618, ic83/ly2603618, ic83/ly2603618, pemetrexed, pemetrexed
SMILES: CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1, CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1, CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1, CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1, CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Has at least one lesion that can be evaluated by Response Evaluation Criteria In Solid
             Tumors (RECIST)

          -  Has fully recovered from all toxicities due to the following:

               1. Local radiation therapy that ended at least 14 days prior to Cycle 1, Day 1.

               2. Surgery.

          -  Has a life expectancy of at least 3 months.

          -  Negative serum pregnancy test.

        Exclusion Criteria:

          -  Is pregnant or breastfeeding.

          -  Is a woman of childbearing potential unwilling to use an approved, effective means of
             contraception according to the institution's standards.

          -  Is a man of childbearing potential unwilling to use an approved, effective means of
             contraception according to the institution's standards.

          -  Has a history of brain metastases, unless adequately treated and without radiologic
             evidence of progressive disease for at least 3 months after completion of therapy.

          -  Has a known active infection.
Clinical trial NCT01089062 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: map0004, iv placebo (saline), placebo inhaler, iv dihydroergotamine mesylate (dhe)
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          1. Able to provide a signed, executed written informed consent

          2. Healthy non-smoking adult volunteers: Male or Female subjects 18 to 45 years old

          3. Female subjects who are practicing adequate contraception

          4. Stable cardiac status

          5. Normal hemoglobin values

          6. Normal Echocardiogram

          7. Normal or not clinically significant 12-lead Electrocardiogram

          8. Demonstrated ability to properly use the Tempo® Inhaler

          9. Subject has not donated blood in the last 56 days

        Exclusion Criteria:

          1. Contraindication to dihydroergotamine mesylate (DHE)

          2. Use of any excluded concomitant medications within the 10 days prior to Visit 1

          3. History of hemiplegic or basilar migraine

          4. Participation in another investigational trial during the 30 days prior to Visit 1
Clinical trial NCT00632424 (phase 1, status: terminated)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: ixabepilone (oral formulation)
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
Reason stopped: 
    business objectives changed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 18 or older

          -  Histologically or cytologically confirmed diagnosis of solid tumor malignancy

          -  Measurable or non-measurable disease as defined by Response Evaluation Criteria In
             Solid Tumors (RECIST) criteria

          -  Karnofsky Performance Status (KPS) of 70-100

          -  Recovered from toxicities resulting from previous therapies

        Exclusion Criteria:

          -  More than 3 prior cytotoxic regimens in the metastatic setting

          -  Current or recent gastrointestinal (GI) disease that would impact the absorption of
             study drug

          -  Inability to swallow whole capsules

          -  Inadequate hepatic and renal function

          -  Function exposure to any epothilone
Clinical trial NCT01684969 (early phase 1, status: withdrawn)
Conditions: nausea, vomiting
ICD codes: R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: haloperidol, placebo
SMILES: OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of accrual and funding is about to expire.
  
Eligibility criteria:

        Inclusion Criteria

          -  Age: patient must be 18 years or older and less than 70 years of age.

          -  Provision of informed consent

          -  No previous adverse reaction to haloperidol

          -  No current use of haloperidol

          -  Good health

          -  No alcohol within 24 hours of the study

          -  No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal,
             hepatic or pulmonary disease.

          -  Normal neurologic exam

        Exclusionary Criteria

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the patient to participate in the study

          -  Recent cerebral trauma

          -  Study will exclude women who are pregnant and/or nursing

          -  Women who are of child bearing potential must have a negative urine pregnancy test.

          -  History of seizures

          -  Taking medications that can interact with haloperidol

          -  Subjects with significant cardiovascular (cardiac conduction deficits),
             gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.
Clinical trial NCT00951301 (phase 1, status: terminated)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: mangosteen juice, placebo juice
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    significantly lower accrual rate than anticipated, time constraints.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Candidates for this study must meet all of the following criteria:

               -  Age >18 years

               -  Documented atrial fibrillation with a clinically indicated cardioversion.

               -  Anticoagulation with therapeutic INR or PTT as per Mayo Clinic cardioversion
                  guidelines.

               -  Provision of written informed consent.

        Exclusion Criteria:

          -  Subjects will be excluded if any of the following conditions apply:

               -  Presence of atrial fibrillation secondary to a reversible cause such as
                  thyrotoxicosis or alcohol use

               -  Myocardial infarction within 1 month, CABG or cardiac surgery including surgical
                  maze or AF radiofrequency ablation within the past 3 months

               -  Presence of an implanted pacemaker, atrial defibrillator, or ventricular
                  defibrillator

               -  History of bleeding diathesis or coagulopathy

               -  Known atrial thrombus or contra-indication to cardioversion

               -  Active infection or collagen vascular disease with active inflammation

               -  Current use of corticosteroids

               -  Gastrointestinal (GI) or genitourinary bleed within the past six months requiring
                  transfusion

               -  Concomitant medical illness (i.e., cancer, congestive heart failure) that may
                  preclude protocol compliance, confound data interpretation or limit
                  life-expectancy to less than one year

               -  Known allergy to juice components

               -  Inability or refusal to cooperate with study procedures

               -  Unsuccessful cardioversion
Clinical trial NCT00719550 (phase 1/phase 2, status: completed)
Conditions: esophagogastric junction adenocarcinoma, gastric cancer, esophageal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: capecitabine, epirubicin, amg 102, cisplatin, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed unresectable locally advanced or metastatic gastric or
             esophagogastric junction (EGJ) adenocarcinoma; tumors of the distal esophagus within 5
             cm of the EGJ are eligible

          -  ECOG performance status 0 or 1

          -  Male or female ≥ 18 years of age

        Exclusion Criteria:

          -  Previous systemic therapy (chemotherapy or biologic therapy) for locally advanced or
             metastatic gastric or esophagogastric adenocarcinoma

          -  Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant
             chemotherapy or chemoradiotherapy.

          -  Subjects with resectable disease or suitable for definitive chemoradiation

          -  Subjects with persistent gastric outlet obstruction, complete dysphagia or feeding
             jejunostomy

          -  Tumors of squamous cell histology

          -  Known central nervous system metastases

          -  Clinically significant upper gastro-intestinal bleeding ≤ 30 days prior to enrollment
             or randomization

          -  Serious or non-healing wound
Clinical trial NCT00278434 (phase 1, status: terminated)
Conditions: cervical cancer, precancerous condition
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90, Y95, D69.9, J94.9, L53.9, G47.01, G47.14, P28.9
Drugs: zoledronate
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Reason stopped: 
    accrual was insufficient to meet study endpoints
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Biopsy confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3

               -  Planning loop excision or cone biopsy

               -  Diagnosis within 2 months prior to study entry

               -  Standard histological grading according to Richart

          -  Visible lesion by colposcopy

               -  No unsatisfactory colposcopy or lesions extending into the endocervical canal
                  that cannot be visualized entirely by colposcopy

          -  No suspicion of invasive cervical cancer by cytology, histology or colposcopy

          -  No cytologic evidence of glandular atypia or dysplasia

        PATIENT CHARACTERISTICS:

          -  Creatinine normal

          -  Screening laboratory values within normal range (e.g., complete blood count, liver
             function tests, renal panel, and electrolytes)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to read and speak English or Spanish

          -  No known hypersensitivity to bisphosphonates

          -  Not immunocompromised

          -  No known HIV positivity

          -  No aspirin-sensitive asthma due to association of bisphosphonates with
             bronchoconstriction

          -  No unexplained abnormal vaginal bleeding

        PRIOR CONCURRENT THERAPY:

          -  No concurrent loop diuretics, aminoglycosides, other nephrotoxic drugs,
             immunosuppressive drugs, or other investigational agents
Clinical trial NCT00403416 (phase 1/phase 2, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: aeb071, mycophenolic acid
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
Eligibility criteria:

        Inclusion criteria

          -  Male and female patients of any race 18 years or older

          -  Adult recipients of a kidney transplant from a deceased or from a living donor

          -  Recipients of a functioning Kidney:. Graft must be functional no later than 36h after
             transplantation.

        Exclusion criteria

          -  Need for medication prohibited by the protocol

          -  Patients or donors infected with hepatitis B or C, or with HIV.

          -  Patients with a history of cancer

          -  Patients with severe systemic infections Patients with heart diseases (own or family
             history) which are associated with an increased risk for arrhythmias.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00076037 (phase 1, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: gm-csf
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV uninfected

          -  Willing to receive HIV test results

          -  Good general health

          -  One of the following major histocompatibility (MHC) alleles: HLA A3, B7, or B8

          -  Acceptable methods of contraception for females of reproductive potential

          -  Hepatitis B surface antigen negative

          -  Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is
             positive

          -  Access to participating site and available for follow-up during the 15 month study

        Exclusion Criteria:

          -  HIV vaccines or placebos in prior HIV vaccine trial

          -  Immunosuppressive medications within 168 days prior to first study vaccine
             administration

          -  Blood products within 120 days prior to first study vaccine administration

          -  Immunoglobulin within 60 days prior to first study vaccine administration

          -  Live attenuated vaccines within 30 days prior to first study vaccine administration

          -  Investigational research agents within 30 days prior to first study vaccine
             administration

          -  Subunit or killed vaccines within 14 days prior to first study vaccine administration

          -  Current tuberculosis prophylaxis or therapy

          -  Serious adverse reaction to a vaccine. A person who had an adverse reaction to
             pertussis vaccine as a child is not excluded.

          -  Hypersensitivity to egg products or yeast-derived products

          -  Autoimmune disease or immunodeficiency

          -  Active syphilis

          -  Unstable asthma

          -  Type 1 or Type 2 diabetes mellitus

          -  Thyroid disease requiring treatment in the past 12 months

          -  Serious angioedema within the past 3 years

          -  Uncontrolled hypertension

          -  Bleeding disorder

          -  Malignancy unless it has been surgically removed and, in the opinion of the
             investigator, is not likely to recur during the study period

          -  Seizure disorder requiring medication within the past 3 years

          -  Asplenia

          -  Mental illness that would interfere with compliance with the protocol

          -  Other conditions that, in the judgment of the investigator, would interfere with the
             study

          -  Pregnant or breast-feeding